Cargando…

Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model

Praliciguat is a soluble guanylate cyclase stimulator that elicits hemodynamic, anti-inflammatory, and antifibrotic effects in preclinical models of metabolic dysfunction. We assessed the metabolic effects of praliciguat in a mouse diet-induced obesity (DIO) model housed at thermoneutrality. At 6 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartzkopf, Chad D., Hadcock, John R., Liu, Guang, Germano, Peter, Roux, Julien, Shea, Courtney M., Buys, Emmanuel S., Jones, Juli E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931041/ https://www.ncbi.nlm.nih.gov/pubmed/35308230 http://dx.doi.org/10.3389/fphar.2022.852080

Ejemplares similares

SUN-662 Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Improves Lipid Handling and Insulin Sensitivity in Diet-Induced Obese Mice
por: Schwartzkopf, Chad D, et al.
Publicado: (2020)

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
por: Correia, Susana S., et al.
Publicado: (2021)

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats
por: Banijamali, Ali R., et al.
Publicado: (2020)

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
por: Correia, Susana S., et al.
Publicado: (2021)

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
por: Hanrahan, John P., et al.
Publicado: (2019)

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma
por: Buys, Emmanuel S., et al.
Publicado: (2014)

Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress
por: Costell, Melissa H., et al.
Publicado: (2012)

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy
por: Hu, Bo-ang, et al.
Publicado: (2023)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021
por: Jia, Xiao-Yan, et al.
Publicado: (2022)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes
por: Ge, Pei, et al.
Publicado: (2016)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

Gender-Specific Modulation of the Response to Arterial Injury by Soluble Guanylate Cyclase α1
por: Vermeersch, Pieter, et al.
Publicado: (2009)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
por: Thoonen, Robrecht, et al.
Publicado: (2015)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

A new small molecule inhibitor of soluble guanylate cyclase
por: Mota, Filipa, et al.
Publicado: (2015)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Activation mechanism of human soluble guanylate cyclase by stimulators and activators
por: Liu, Rui, et al.
Publicado: (2021)

Genetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase α(1) deficient mice
por: Buys, Emmanuel S, et al.
Publicado: (2011)

Cardiac soluble guanylate cyclase protects against the cardiac dysfunction induced by chronic doxorubicin treatment in mice
por: Vandenwijngaert, Sara, et al.
Publicado: (2015)

Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase–dependent manner
por: Cauwels, Anje, et al.
Publicado: (2009)

Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet‐fed rabbits
por: Tawa, Masashi, et al.
Publicado: (2021)

Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
por: Miller, Thomas W, et al.
Publicado: (2009)

Stimulators and Activators of Soluble Guanylate Cyclase: Review and Potential Therapeutic Indications
por: Nossaman, Bobby, et al.
Publicado: (2012)

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
por: Rogers, Natasha M., et al.
Publicado: (2014)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development
por: Gileadi, Opher
Publicado: (2014)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Khalid, Rana Rehan, et al.
Publicado: (2020)

The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in experimental non‐alcoholic steatohepatitis
por: Flores‐Costa, Roger, et al.
Publicado: (2018)

Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE
por: Vandenwijngaert, Sara, et al.
Publicado: (2015)

From biochemical and structural studies of soluble guanylate cyclase toward drug design
por: Laffly, Emmanuelle, et al.
Publicado: (2009)

Biochemical and structural characterization of C-terminal constructs of bovine soluble guanylate cyclase
por: Seeger, Franziska, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_sj5gp71rtsl48e4lhke5vc7mkb